CENTER FOR CLINICAL TRIALS Ongoing Clinical Trials DEPARTMENT OF MEDICINE (24) Arthritis
TITLE: A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen [PRECISION: Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs. Ibuprofen Or Naproxen] PROTOCOL NUMBER: A3191172 PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD STUDY COORDINATOR : Irene Guna CONTACT NUMBER: 09228372121 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00346216?term=A3191172&rank=1 TITLE: A Phase IIB, 12 Week Radomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Evaluate Efficacy, Safety And Tolerability Of 2, 4 And 6 Mg Of Revamilast In Patients With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate PROTOCOL NUMBER: GRC 4039-203 PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD STUDY COORDINATOR : Irene Guna CONTACT NUMBER: 09228372121 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01430507?term=GRC+4039-203&rank=1 TITLE: A Randomized, Double-Blind, Parallel-Group, Phase 1 Study To Evaluate The Initial Pharmacokinetics, Efficacy, And Safety Of CT-P13 Compared With Remicade When Co-Administered With Methotrexate In Patients With Active Rheumatoid Arthritis PROTOCOL NUMBER: CT-P13 1.2 PRINCIPAL INVESTIGATOR : Dr. Sandra V. Navarra, MD; Celltrion, Inc. STUDY COORDINATOR : Irene Guna CONTACT NUMBER: 09228730601 For more details, call the number above. TITLE : A Randomized, Double-Blind, Parallel-Group, Phase 3 Study To Demonstrate Equivalence In Efficacy And Safety Of CT-P13 Compared With Remicade When Co-Administered With Methotrexate In Patients With Active Rheumatoid Arthritis PROTOCOL NUMBER : CT-P13 3.1 PRINCIPAL INVESTIGATOR : Sandra V. Navarra, MD STUDY COORDINATOR : Irene Guna CONTACT NUMBERS : 09228730601 For more details, call the number above.
TITLE : A Randomized, Double-Blind, Parallel Group Study Of The Safety And Effect On Clinical Outcome Of Tocilizumab SC Versus Tocilizumab IV, In Combination With Traditional Disease Modifying Anti-Rheumatic Drugs (Dmards), In Patients With Moderate To Severe Active Rheumatoid Arthritis PROTOCOL NUMBER : WA22762 PRINCIPAL INVESTIGATOR : Juan J. Lichauco, MD STUDY COORDINATOR : Irene Guna CONTACT NUMBERS : 09228730601 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01194414?term=WA22762&rank=2 TITLE : A Two-Part, Phase 1 Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study To Assess The Pharmacokinetics, Safety, And Tolerability Of MK-8808 And To Compare The Pharmacokinetics Of MK-8808 With Rituximab (Mabthera™) In Patients With Rheumatoid Arthritis (RA) PROTOCOL NUMBER : MK-8808 002 PRINCIPAL INVESTIGATOR : Paul V. Santos-Estrella, MD STUDY COORDINATOR : N/A CONTACT NUMBERS : 09228825441 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01390441?term=MK-8808+002&rank=1 TITLE : A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of Secukinumab To Demonstrate The Efficacy At 24 Weeks And To Assess The Long Term Safety, Tolerability And Efficacy Up To 2 Years In Patients With Active Psoriatic Arthritis/ CAIN457F2306 (Phase III) PROTOCOL NUMBER : CAIN457F2306 PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD STUDY COORDINATOR : Irene Guña CONTACT NUMBERS : 09228372121 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01392326?term=CAIN457F2306&rank=1 TITLE : A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial Of Golimumab, a Fully Human Anti-TNF? Monoclonal Antibody, Administered Subcutaneously, In Methotrexate-Naive, Subjects With Active Rheumatoid Arthritis (C054TO5) PROTOCOL NUMBER : C054TO5 PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD STUDY COORDINATOR : Irene Guna CONTACT NUMBERS : 09228372121 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00973479?term=anti- TNF+golimumab&rank=8 Diabetes
TITLE: A Multicenter, International, Randomized, 2x2 Factorial Design Study To Evaluate The Effects Of Lantus (Insulin Glargine) Vs Standard Care, And Of Omega-3 Fatty Acids Vs Placebo In Reducing Cardiovascular Mortality In High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), Or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Insulin Glargine Intervention PROTOCOL NUMBER: HOE901-4032 PRINCIPAL INVESTIGATOR : Ricardo E. Fernando, MD STUDY COORDINATOR : Paz Figueroa CONTACT NUMBER: 8595555 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00069784?term=origin%2C+insulin+glargine&rank=2 TITLE : A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel- Group, Multicenter Study To Determine The Efficacy And Safety Of Albiglutide When Used In Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, And Metformin Plus Placebo In Subjects With Type 2 Diabetes Mellitus PROTOCOL NUMBER : GLP112753 PRINCIPAL INVESTIGATOR : Gabriel V. Jasul, MD STUDY COORDINATOR : Cristobal Pesa CONTACT NUMBERS : 09285047050 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00838903?term=112753&rank=1 TITLE : A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study To Determine The Efficacy And Safety Of Albiglutide Administered In Combination With Metformin And Glimepiride Compared With Metformin Plus Glimepiride And Placebo And With Metformin Plus Glimepiride And Pioglitazone In Subjects With Type 2 Diabetes Mellitus PROTOCOL NUMBER : GLP112757 PRINCIPAL INVESTIGATOR : Gabriel V. Jasul, MD STUDY COORDINATOR : Cristobal Pesa CONTACT NUMBERS : 09285047050 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00839527?term=albiglutide%2C+metformin%2Cglimepiride&rank=1 TITLE : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin In Addition To Standard Of Care In Subjects With Type 2 Diabetes And Acute Coronary Syndrome (Phase 3b); PROTOCOL NUMBER : (SYR-322_402) PRINCIPAL INVESTIGATOR : Gabriel V. Jasul Jr, MD STUDY COORDINATOR : Cristobal Pesa CONTACT NUMBERS : 09285047050 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00968708?term=322_402&rank=1 TITLE : Asian Treat To Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating The Effectiveness And Safety Of Physician Versus Patient-Led Initiation And Titration Of Insulin Glargine In Type 2 Diabetes Mellitus (ATLAS Study) PROTOCOL NUMBER : LANTU_R_04889 PRINCIPAL INVESTIGATOR : Roberto C. Mirasol, MD STUDY COORDINATOR : Luna Reyes CONTACT NUMBERS : 09176023414 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01169818?term=04889&rank=2 TITLE : A Phase III Randomised, Double-Blind, Active-Controlled Parallel Group Efficacy And Safety Study Of BI 10773 Compared To Glimepiride Administered Orally During 104 Weeks In Patients With Type 2 Diabetes Mellitus And Insufficient Glycaemic Control Despite Metformin Treatment PROTOCOL NUMBER : BI 1245.28 PRINCIPAL INVESTIGATOR : Ricardo E. Fernando, MD STUDY COORDINATOR : Alice Vega CONTACT NUMBERS : 7230101 6336 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01167881?term=1245.28&rank=1 TITLE : A Multicenter, Randomized, Double-Blind, Active-Controlled Study To Evaluate The Durability Of The Efficacy And Safety Of Alogliptin Compared To Glipizide When Used In Combination With Metformin In Subjects With Type 2 Diabetes PROTOCOL NUMBER : SYR-322_305 PRINCIPAL INVESTIGATOR : Elizabeth Ann Fernando-Catindig, MD STUDY COORDINATOR : Levita C. Vitug CONTACT NUMBERS : 7230101 6336 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00856284?term=322_305&rank=1 TITLE : A Multinational, Multicenter, Post-Authorization, Prospective Observational Cohort Study To Assess The Profile Of Vidagliptin And The Fixed-Dose Combination Of Vildagliptin/Metformin Relative To Comparator Oral Anti-Diabetic Drugs In Patients With Type2 Diabetes In a Real-World Setting PROTOCOL NUMBER : CLAF237A2403 PRINCIPAL INVESTIGATOR : Gabriel V. Jasul Jr., MD STUDY COORDINATOR : Cristobal C. Pesa CONTACT NUMBERS : 09286349420 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT00099866?term=profile+of+vildagliptin%2Fmetformin&rank=8
TITLE : An Observational, Multinational, Multi-Center Prospective Cohort Study To Assess Effectiveness, Safety And Tolerability Of Treatment With Vildagliptin Or Single Pill Combination Of Vildagliptin/Metformin
In Type 2 Diabetes Mellitus In Real-World Setting/ GUARD Study PROTOCOL NUMBER : CLAF237A-MAX-PH-01 PRINCIPAL INVESTIGATOR : Reynaldo F. Rosales, MD STUDY COORDINATOR : Madonna Lozano CONTACT NUMBERS : 09178592296 For more details, call the number above. TITLE : A Multicentre, International, Randomised, Parallel Group, Double Blind Study To Evaluate Cardiovascular Safety Of Linagliptin Versus Glimepiride In Patients With Type 2 Diabetes Mellitus At High Cardiovascular Risk PROTOCOL NUMBER : BI1218.74 / CAROLINA TRIAL PRINCIPAL INVESTIGATOR : Gabriel V. Jasul, Jr., MD STUDY COORDINATOR : Cristobal Pesa CONTACT NUMBERS : 09285047050 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01243424?term=1218.74&rank=1 TITLE : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Subcutaneous LY2127399 In Patients With Systemic Lupus Erythematosus (SLE) PROTOCOL NUMBER : H9B-MC-BCDS PRINCIPAL INVESTIGATOR : Sandra V. Navarra, MD; Eli Lilly And Company STUDY COORDINATOR : Irene Guna CONTACT NUMBERS : 09228787381 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01196091?term=H9B-MC-BCDS&rank=1 TITLE: Evaluation Of Chronic Kidney Disease Practice Pattern Through The Global Renal Information Database (GRID) Project PROTOCOL NUMBER : GRID-CKD Project PRINCIPAL INVESTIGATOR : Benjamin A. Balmores, MD STUDY COORDINATOR : N/A CONTACT NUMBER : 7230101 4735 For more details, call the number above. TITLE: A Post-Marketing Surveillance Study On The Effectiveness, Safety And Tolerability Of Telbivudine (Sebivoâ®) 600 Mg Once Daily In The Treatment Of Chronic Hepatitis B Among Filipino Patients PROTOCOL NUMBER : CLDT600APH01 PRINCIPAL INVESTIGATOR : Randy Mercado, MD STUDY COORDINATOR : N/A CONTACT NUMBER : 8159371 loc.329 For more details, call the number above. TITLE: Renvela® Post Marketing Surveillance Study In The Philippines Under The Modified Release Program PROTOCOL NUMBER : Renvela® PRINCIPAL INVESTIGATOR : Benjamin A. Balmores, MD STUDY COORDINATOR : N/A CONTACT NUMBER : 7230101 6447 For more details, call the number above.
TITLE : A Descriptive Study Of The Efficacy And Safety Of ONGLYZA (Saxagliptin) Under Conditions Of Actual Use In The Philippines PROTOCOL NUMBER : D1680L0007 PRINCIPAL INVESTIGATOR : Michael L. Villa, MD STUDY COORDINATOR : N/A CONTACT NUMBER : 777 8805 For more details, click this link http://www.clinicaltrials.gov/ct2/show/NCT01223456?term=onglyza+saxagliptin&rank=17 TITLE : A Comparison Of Tuberculin Skin Test And Interferon-Gamma Release Assay Test Response In Individuals With Strong Risk Factors For The Development Of Tuberculosis Due To Immune Compromise With The Same Response In Healthy Household Members Without Immune Compromise PROTOCOL NUMBER : 242-11-222 PRINCIPAL INVESTIGATOR : Paul V. Santos Estrella, MD STUDY COORDINATOR : Irene Guna CONTACT NUMBER :09228825441 For more details, call the number above.
United States Court of Appeals FOR THE EIGHTH CIRCUIT Before HANSEN, Chief Judge,1 and McMILLIAN and BEAM, Circuit Judges. Strategic Directions Group, Inc. (SDG) appeals from a judgment of the districtcourt2 granting summary judgment in favor of Bristol-Myers Squibb Company(Bristol-Myers) in this trade secrets and breach of contract case. We affirm. 1The Honorable David R. Hansen became
Bladder Treatment Options Following an assessment with a competent healthcare practitioner, a treatment plan will be discussed and agreed with you, which may include any or all of the following: Fluid changes Recording the amount drunk and the volumes of urine produced can help to identify the optimum amount of fluid an individual requires. Considering the amount of caffeine intake